Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization

References

• Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343:769-72
   PubMed Web of Science ®Google Scholar
• Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
   PubMed Web of Science ®Google Scholar
• Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91
   PubMed Web of Science ®Google Scholar
• Moore RA. The hidden costs of arthritis treatment and the cost of new therapy: the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology (Oxford) 2002;41 (Suppl. 1):7-15
   PubMed Web of Science ®Google Scholar
• Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82
   PubMed Web of Science ®Google Scholar
• Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685-93
   PubMed Web of Science ®Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-38S
   PubMedGoogle Scholar
• Moore RA, Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999;2:45-55
   Google Scholar
• Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
   Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G. et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; CD002296
   Google Scholar
• Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-9
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34
   Google Scholar
• Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26
   Google Scholar
• Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:1091-7
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
   PubMed Web of Science ®Google Scholar
• Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9
   PubMed Web of Science ®Google Scholar
• Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications: review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19:1051-61
   PubMed Web of Science ®Google Scholar
• Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12
   PubMed Web of Science ®Google Scholar
• Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606
   PubMed Web of Science ®Google Scholar
• Simon LS. Risk factors and current NSAID use. J Rheumatol 1999;26:1429-31
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46
   PubMed Web of Science ®Google Scholar
• American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview, IL: American Pain Society, 2002
   Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Osteoarthritis. National clinical guideline for care and management in adults. Available at: http://www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf [Last accessed 8 June 2008]
   Google Scholar
• Smalley W, Stein CM, Arbogast PG, et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-200
   PubMed Web of Science ®Google Scholar
• Parente F, Cucino C, Gallus S, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month study. Aliment Pharmacol Ther 2003;17:1503-06
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42 (Suppl. 3):iii23-iii31
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003;18:1137-47
   PubMed Web of Science ®Google Scholar
• Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 2004;38:760-3
   PubMed Web of Science ®Google Scholar
• Erdeljic V, Francetic I, Macolic Sarinic V, et al. Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study. Pharm World Sci 2006;28:318-25
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337-45
   PubMed Web of Science ®Google Scholar
• van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002;24:100-103
   PubMed Web of Science ®Google Scholar
• Vonkeman HE, Fernandes RW, van de Laar MA. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007;45:281-8
   PubMed Web of Science ®Google Scholar
• Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26:265-75
   PubMed Web of Science ®Google Scholar
• Abraham NS, El Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129:1171-8
   PubMed Web of Science ®Google Scholar
• van der Bij S, Breekveldt-Postma N, Goettsch WG, et al. Impact of proton pump inhibitor (PPI) therapy and nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) treatment adherence on gastrointestinal (GI) hospitalizations. APLAR J Rheumatol 2006;9 (Suppl 1):77
   Google Scholar
• DIN-LINK database system. Compufile Ltd. Available at: http://www.compufile.co.uk/din-link.htm [Last accessed 1 January 2007]
   Google Scholar
• Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007;24:121-31
   PubMed Web of Science ®Google Scholar
• Coté GA, Rice JP, Bulsiewicz W, et al. Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users. Am J Gastroenterol 2008;103(5):1097-103
   PubMed Web of Science ®Google Scholar
• Woolf AD, Zeidler H, Haglund U, et al. Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis 2004;63:342-7
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74
   PubMed Web of Science ®Google Scholar
• Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Lowry SC, Lanza FL, et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2006;23:1489-98
   PubMed Web of Science ®Google Scholar